BioLife Solutions/$BLFS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioLife Solutions
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Ticker
$BLFS
Sector
Primary listing
Employees
155
Headquarters
Website
BLFS Metrics
BasicAdvanced
$1.5bn
-
-$0.07
1.97
-
Price and volume
Market cap
$1.5bn
Beta
1.97
52-week high
$33.14
52-week low
$17.86
Average daily volume
1.6m
Financial strength
Current ratio
7.299
Quick ratio
5.153
Long term debt to equity
2.698
Total debt to equity
3.991
Profitability
EBITDA (TTM)
4.321
Gross margin (TTM)
63.76%
Net profit margin (TTM)
-2.91%
Operating margin (TTM)
-0.55%
Effective tax rate (TTM)
-0.87%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
-0.09%
Return on equity (TTM)
-3.09%
Valuation
Price to revenue (TTM)
14.899
Price to book
4.13
Price to tangible book (TTM)
9.63
Price to free cash flow (TTM)
194.413
Free cash flow yield (TTM)
0.51%
Free cash flow per share (TTM)
0.162
Growth
Revenue change (TTM)
29.89%
Earnings per share change (TTM)
-68.37%
3-year revenue growth (CAGR)
-13.06%
10-year revenue growth (CAGR)
31.06%
3-year earnings per share growth (CAGR)
-72.53%
10-year earnings per share growth (CAGR)
-14.99%
What the Analysts think about BLFS
Analyst ratings (Buy, Hold, Sell) for BioLife Solutions stock.
BLFS Financial Performance
Revenues and expenses
BLFS Earnings Performance
Company profitability
BLFS News
AllArticlesVideos
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Business Wire·7 days ago
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
MarketBeat·1 week ago
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
Benzinga·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.